Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease
Author:
Affiliation:
1. Hyogo Prefectural Himeji Cardiovascular Center, Division of Cardiovascular Medicine
2. Hyogo Prefectural Himeji Cardiovascular Center, Division of Diabetes and Endocrinology
Publisher
Japan Atherosclerosis Society
Subject
Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine
Link
https://www.jstage.jst.go.jp/article/jat/27/7/27_50807/_pdf
Reference40 articles.
1. 2) Malmberg K, Yusuf S, Gerstein HC, Brown J, Zhao F, Hunt D, Piegas L, Calvin J, Keltai M, Budaj A. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndrome) Registry. Circulation, 2000; 102: 1014-1019
2. 3) Vallon V. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu Rev Med, 2015; 66: 255-270
3. 4) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardioavascular outcomes, and mortality in type 2 diabetes. N Engl J Med, 2015; 373: 2117-2128
4. 5) Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: Results from the CANVAS Program (Canagliflozi Cardiovascular Assessment Study). Circulation, 2018; 137: 323-334
5. 6) Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation, 2016; 134: 752-772
Cited by 32 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The current landscape for diabetes treatment: Preventing diabetes-associated CV risk;Atherosclerosis;2024-07
2. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project);JMIR Research Protocols;2024-05-29
3. SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis;Frontiers in Cardiovascular Medicine;2024-01-11
4. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project) (Preprint);2024-01-04
5. Antihypertensive Effects of SGLT-2 Inhibitors and Progress in Research;Advances in Clinical Medicine;2024
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3